Abstract: The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.

Abstract: A system and method for dynamically a visual function of a subject are provided where the system and method account for fixation eye movement(s); saccade eye movement (s); smooth pursuit eye movement(s); optokinetic nystagmus eye movement(s); and/or blink eye movement, the system for dynamically assessing a visual function of a subject is provided, comprising: i) a visual display; ii) an eye-tracking device configured to detect a gaze position of at least one eye of the subject; and updating in real time the appearance of a first stimulus to provide a second stimulus based on at least on of the updated evidence-of-visibility score and the updated evidence-of-trackability score for the first visual stimulus.

Abstract: The present disclosure describes methods of treating a central nervous system condition associated with oxidative stress using a 5-lipoxigenase activating protein (FLAP) inhibitor, for example, N-acetylcysteine or nordihydroguaiaretic acid. The present disclosure also describes methods of treating a central nervous system condition with N-acetylcysteine and a second therapeutic agent such as prostaglandin E2.

Abstract: This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.

Abstract: A method for treating a subject having or likely to develop a neurodegenerative disease, wherein the subject is administered a pharmaceutically effective amount of a compound within the generic structure (1) wherein R1 is either —R or —SR, wherein R is a hydrocarbon group containing 1-20 carbon atoms and optionally containing one or more heteroatoms selected from oxygen, nitrogen, and sulfur; and R2 is selected from the group consisting of —OR?, —OPO32?, and —OC(O)R?, wherein R? is a hydrogen atom or a hydrocarbon group containing 1-6 carbon atoms; and wherein Formula (1) may include pharmaceutically acceptable salts, solvates, and polymorphs thereof, and wherein the subject may be identified as positive, before or during treatment, for at least one marker, including, for example, amyloid plaques, neurofibrillary tangles, decline in brain glucose metabolism, decline in thiamine diphosphate-dependent enzyme activity, and increase in advanced glycation end products.

Abstract: The present disclosure describes methods of treating a central nervous system condition associated with oxidative stress using a 5-lipoxigenase activating protein (FLAP) inhibitor, for example, N-acetylcysteine or nordihydroguaiaretic acid. The present disclosure also describes methods of treating a central nervous system condition with N-acetylcysteine and a second therapeutic agent such as prostaglandin E2.

Abstract: Methods, systems and devices for determining contrast sensitivity function in a subject without requiring perceptual report by the subject.

Abstract: This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.